⁹⁰Yttrium–ibritumomab tiuxetan: a novel treatment for non-Hodgkin’s lymphoma

Authors: Kristie A Blum; Nancy L Bartlett

Source: Expert Opinion on Biological Therapy, Volume 4, Number 8, 1 August 2004 , pp. 1323-1331(9)

Publisher: Informa Healthcare

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Indolent non-Hodgkin’s lymphomas (NHLs) comprise 35 – 40% of all adult NHLs. No standard curative therapy exists for these malignancies. Newer therapies, including monoclonal antibodies and radioimmunotherapy, have had notable activity in chemotherapy-resistant patients. ⁹⁰Yttrium–ibritumomab tiuxetan is a radioimmunoconjugate approved by the Food and Drug Administration in February 2002 for the treatment of relapsed and refractory, low-grade, follicular or transformed NHL. Reported response rates are 67 – 80%, with a median remission duration of ~ 12 months. Toxicities are primarily neutropenia and thrombocytopenia, with few infectious complications. ⁹⁰Yttrium–ibritumomab tiuxetan is an effective therapeutic alternative for the treatment of NHL.

Keywords: 90Yttrium–ibritumomab tiuxetan; monoclonal antibody; non-Hodgkin’s lymphoma; radioimmunoconjugate; radioimmunotherapy

Document Type: Drug Evaluation

DOI: 10.1517/14712598.4.8.1323

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax Refund Policy